JP Drafts (December 2025)

JP drafts for public comments (December 1, 2025 to February 28, 2026)

New monographs

• Solifenacin Succinate[278KB](001-2512eng.pdf)
• Solifenacin Succinate Tablets[229KB](002-2512eng.pdf)
• Solifenacin Succinate Orally Disintegrating Tablets[242KB](003-2512eng.pdf)

Ultraviolet-visible reference spectra

• Solifenacin Succinate[76.7KB](004-2512eng.pdf)

 

The guidance to send comments on the JP drafts is as follows:

1. Download the form for comments in Word format[67.0KB]
2. Fill in the form
3. Prepare and attach the supportive data that scientifically validate the comment when appropriate
4. Send it to the email address: JPdraft-eng[at]pmda.go.jp

Note:
For the purpose of security, this email address is partly incorrect. Please replace [at] with @ when sending an email.

Related Information

• Columns (Chemical drug)

 

Note:
The information submitted with the comments may be released to the public whenever necessary (except the individual name, organization, address, telephone & fax numbers and e-mail address or the attached supportive data).
Your comments will be considered for the preparation of JP final drafts, but no individual response will be made to each comment.